Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTONE versus PREDNISOLONE SODIUM PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTONE versus PREDNISOLONE SODIUM PHOSPHATE.
HYDROCORTONE vs PREDNISOLONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Agonist of glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of pro-inflammatory cytokines, and suppression of immune cell activity.
100-500 mg intravenously every 2-6 hours for initial management of adrenal insufficiency; oral maintenance: 20-30 mg daily in divided doses (e.g., 10 mg morning, 5 mg afternoon).
Initial dose: 5-60 mg orally or intravenously once daily or divided every 12-24 hours; range 5-60 mg/day. For acute conditions, 40-60 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (plasma), but biological half-life (duration of HPA axis suppression) is 8–12 hours.
Terminal elimination half-life is 2.1–3.5 hours in adults (mean 2.6 h). Clinical context: Short half-life supports twice-daily dosing for most conditions; prolonged in hepatic impairment (up to 8 h).
Renal (primarily as inactive metabolites; <5% unchanged) and biliary/fecal (minor).
Renal excretion of inactive metabolites (primarily prednisolone) accounts for >80% of elimination; less than 10% excreted unchanged. Biliary/fecal excretion is negligible (<5%).
Category C
Category D/X
Corticosteroid
Corticosteroid